Actively Recruiting
Craniospinal Irradiation in Histone AlteRed Midline Glioma
Led by Tata Memorial Centre · Updated on 2025-01-20
32
Participants Needed
1
Research Sites
200 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Paediatric H3K27/H3G34 mutant diffuse midline gliomas are high grade gliomas that arise in midline structures/cerebral hemispheres and are known to have dismal outcomes. Standard treatment includes definitive radiation therapy to primary site along with concurrent temozolomide chemotherapy following histological confirmation with a biopsy. Studies have shown poorer outcomes in the paediatric age group compared to that of adults and an increased risk to fail/recur in the leptomeninges(covering of brain and spinal cord). The following study is planned in order to assess the benefit of craniospinal irradiation(delivering radiotherapy to brain, spinal cord and its covering membrane in this high risk population. Thereby the investigator aim to improve survival in newly diagnosed histone mutant pediatric midline gliomas in the upfront setting. Patterns of disease failure, treatment related toxicities and quality of life will also be assessed as a part of this study. If proven beneficial, this study will influence how patients with this diagnosis will be treated in the future.
CONDITIONS
Official Title
Craniospinal Irradiation in Histone AlteRed Midline Glioma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed biopsy proven histone altered diffuse midline glioma
- Age 3 to less than 18 years at time of diagnosis
- Karnofsky/Lansky Performance Score of 70 or higher
- Provided written informed consent or assent
- No prior therapy except debulking surgery or biopsy
You will not qualify if you...
- Recurrent or progressive disease
- Clinical features or family history indicating inherited cancer predisposition such as Constitutional Mismatch Repair Deficiency (CMMRD)
- Previous history of malignancy
- Unwilling or unlikely to comply with proposed therapy and follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tata Memorial Hospital
Mumbai, India
Actively Recruiting
Research Team
A
Abhishek Chatterjee, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here